Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be using an inhaled medicine called treprostinil.
- You have scarring lung disease (interstitial lung disease), like idiopathic interstitial pneumonia, chronic hypersensitivity pneumonitis, or connective tissue disease related ILD.
- You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) confirmed by a heart catheterization test.
- You can walk at least 100 meters (about 1 city block) in 6 minutes.
- You do not have other types of lung or heart conditions that could cause similar symptoms.
- You have not started a new lung rehab program or had a worsening of your lung disease in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
This trial tests if pioglitazone, a medicine used for diabetes, can help people with high blood pressure in their lungs caused by chronic lung disease. The goal is to see if it improves how your cells use energy.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.